Difference between revisions of "Mirtazapine-fluoxetine"

From Psychiatrienet
Jump to: navigation, search
Line 6: Line 6:
 
| start =   
 
| start =   
 
{{startFluoxetine}}
 
{{startFluoxetine}}
| info =
+
 
{{lowlevels}}
 
 
}}
 
}}

Revision as of 08:06, 14 October 2015

Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
Fluoxetine
Type Antidepressant
Group SSRI
links
Medscape Fluoxetine
PubChem 3386
PubMed Fluoxetine
Kompas (Dutch) Fluoxetine
Wikipedia Fluoxetine

Switch medication from mirtazapine to fluoxetine.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Before day 1: Gradually reduce dosage of mirtazapine to a maximum of 30 mg/day, when this dosage is > 30 mg/day.
  • Day 1: Reduce dosage of mirtazapine to 15 mg/day.
  • Day 8: Stop administration of mirtazapine.
Eenrichtingbord.png Start fluoxetine
  • Day 2: Start administration of fluoxetine in a dosage of 20 mg/day.
  • After 3 weeks: If necessary, gradually increase dosage of fluoxetine to max. 60 mg/day


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.